WILMINGTON, Del., Sept. 23, 2015 /PRNewswire/ -- Rigrodsky
& Long, P.A.:
- Do you, or did you, own shares of Northwest Biotherapeutics,
Inc. (NASDAQ CM: NWBO)?
- Did you purchase your shares between March 8, 2013 and August
20, 2015, inclusive?
- Did you lose money in your investment?
Rigrodsky & Long, P.A. announces that a complaint has been
filed in the United States District Court for the District of
Maryland on behalf of all persons
or entities that purchased the common stock of Northwest
Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the
"Company") (NASDAQ CM: NWBO) between March
8, 2013 and August 20, 2015,
inclusive (the "Class Period"), alleging violations of the
Securities Exchange Act of 1934 against the Company and certain of
its officers (the "Complaint").
If you purchased shares of Northwest Biotherapeutics during the
Class Period, or purchased shares prior to the Class Period and
still hold Northwest Biotherapeutics, and wish to discuss this
action or have any questions concerning this notice or your rights
or interests, please contact Timothy J. MacFall, Esquire or
Peter Allocco of Rigrodsky &
Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by
e-mail to info@rl-legal.com; or at:
http://rigrodskylong.com/investigations/northwest-biotherapeutics-inc-nwbo.
The Complaint alleges that throughout the Class Period,
defendants made materially false and misleading statements, and
omitted materially adverse facts, about the Company's business,
operations and prospects. As a result of defendants' alleged
false and misleading statements, the Company's stock traded at
artificially inflated prices during the Class Period.
According to the Complaint, on August 21,
2015, pre-market, news broke that the Company's Phase 3
DCVax-L brain cancer treatment clinical trial in Germany was temporarily suspended. Later
on the same day, the Company stated that new screening of patient
candidates for the trial had been temporarily suspended while the
Company submitted certain information from the trial for regulatory
review.
On this news, shares in Northwest Biotherapeutics dropped over
21%, closing at $6.96 per share on
August 21, 2015, on heavy trading
volume.
If you wish to serve as lead plaintiff, you must move the Court
no later than October 26,
2015. A lead plaintiff is a representative party
acting on behalf of other class members in directing the
litigation. Any member of the proposed class may move the
court to serve as lead plaintiff through counsel of their choice,
or may choose to do nothing and remain an absent class member.
Attorney advertising. Prior results do not guarantee a
similar outcome.
CONTACT:
Rigrodsky & Long, P.A.
Timothy J. MacFall, Esquire
Peter Allocco
(888) 969-4242
(516) 683-3516
Fax: (302) 654-7530
info@rl-legal.com
http://www.rigrodskylong.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-rigrodsky--long-pa-announces-a-securities-fraud-class-action-lawsuit-has-been-filed-against-northwest-biotherapeutics-inc-300148207.html
SOURCE Rigrodsky & Long, P.A.